ClinicalTrials.gg

Program

BI 1815368

A development code. Also written as “BI 1815368 (C-14)”, “BI 1815368 (C-13)” and “BI 1815368 formulation 1”.

In Boehringer Ingelheim's pipeline, Oral vascular modulator. Its studies are mostly in Macular Edema, led by Boehringer Ingelheim.

Furthest: phase 2, since Apr 30, 20257 company-led studies, 1 open or runningNext primary completion: Mar 1, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim71 open or runningphase 2since Apr 30, 2025Apr 14, 2022Mar 1, 2028phase 2 · NCT06962839
  • Named in Boehringer Ingelheim’s own pipeline as BI 1815368, phase 2, as of Aug 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 14, 2022First study: phase 1 study in HealthyFirst studyNCT05337592 · 72 enrolled · Germany
  2. May 5, 2023Phase 1 study in HealthyNCT05857878 · 59 enrolled · Belgium
  3. Jul 19, 2023Phase 1 study in HealthyNCT05965583 · 14 enrolled · Germany
  4. Jul 3, 2024Phase 1 study in HealthyNCT06494774 · 26 enrolled · Japan
  5. Oct 22, 2024Phase 1 study in HealthyNCT06655220 · 14 enrolled · Germany
  6. Apr 30, 2025Phase 2 study in Macular EdemaNCT06962839 · 300 planned · United States, China, Czechia and more
  7. Jul 3, 2026Phase 1 study in HealthyNCT07693218 · 8 enrolled · Netherlands
  8. Oct 16, 2026Primary completion moved from 2027-09-01 to 2028-03-01Date moved laterphase 2 · +6 months · NCT06962839

Ahead

  1. Mar 1, 2028Primary completion: phase 2 study in Macular EdemaNCT06962839

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Oral vascular modulator”the company's pipeline, read by Claude · source

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07693218Healthy · Netherlands1CompletedAug 29, 20268
NCT06962839Macular Edema · United States, China, Czechia and more2RecruitingMar 1, 2028300
NCT06655220Healthy · Germany1CompletedDec 8, 202414
NCT06494774Healthy · Japan1CompletedNov 13, 202426
NCT05965583Healthy · Germany1CompletedOct 24, 202314
NCT05857878Healthy · Belgium1CompletedJun 6, 202459
NCT05337592Healthy · Germany1CompletedOct 18, 202272

How it is read

Names in the registry

  • “BI 1815368”, 5 entries
  • “BI 1815368 (C-14)”, 1 entry
  • “BI 1815368 (C-13)”, 1 entry
  • “BI 1815368 formulation 1”, 1 entry
  • “BI 1815368 formulation 2”, 1 entry

Codes read as this program: BI1815368.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.